Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but filing text confirms "Synthetic Blood International, Inc.")
Reporting Period: Quarterly period ended January 31, 2000 (Form 10-Q).
Status: Development Stage Company in pre-clinical trial phase.
Going Concern: Substantial doubt exists regarding the company's ability to continue as a going concern due to accumulated losses of $10.98 million and a working capital deficit of $432,415. Continuation depends on obtaining additional financing and FDA approval.
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 2000 | Nine Months Ended Jan 31, 2000 | Accumulated (Development Stage) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(181,672) | $(580,245) | $(10,982,244) |
| Research & Development Expenses | $69,764 | $140,007 | $3,303,931 |
| General & Administrative Expenses | $109,330 | $456,090 | $7,619,937 |
| Cash and Cash Equivalents (Ending) | $39,060 | $39,060 | $39,060 |
| Working Capital Deficit | $(432,415) | $(432,415) | $(432,415) |
| Total Liabilities | $585,014 | $585,014 | $585,014 |
| Stockholders' Deficiency | $(205,715) | $(205,715) | $(205,715) |
Liquidity: Net cash used in operating activities for the nine months ended Jan 31, 2000, was $589,496. Net cash provided by financing activities was $461,552.
Material Changes vs. Prior Period
- Net Loss: The net loss for the three months ended Jan 31, 2000, increased to $181,672 from $151,948 in the prior year, driven by higher R&D expenses. For the nine-month period, the net loss decreased to $580,245 from $617,013 due to reduced G&A expenses and increased other income.
- R&D Expenses: Increased by $27,400 (3-month) and $40,212 (9-month) compared to the prior year periods, attributed to increased salaries and contract wages for research activity.
- G&A Expenses: Decreased by $8,177 (3-month) and $69,131 (9-month) compared to the prior year, primarily due to reduced wages and consulting fees, partially offset by office setup costs in California.
- Cash Position: Cash and cash equivalents declined from $193,013 at April 30, 1999, to $39,060 at January 31, 2000.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: The company requires significant additional financing to complete pre-clinical testing and proceed to Phase I, II, and III human trials. Management is pursuing strategic alliances and joint ventures.
- Risks:
- Substantial doubt about the ability to continue as a going concern.
- No assurance of FDA approval for products.
- Risk of inability to raise adequate financing, which could force delays or elimination of product programs.
- Uncertainties regarding patent enforcement and manufacturing scalability.
- Unusual Items:
- Stock Subscription Receivable: A $1.2 million receivable from a stockholder (related to 9 million shares) is recorded as a reduction of Stockholders' Deficiency.
- Other Income: A $15,000 increase in other income for the nine-month period resulted from a vendor settlement.
- Subsequent Event: Post-period (after Jan 31, 2000), the company issued 3.6 million shares for $1.0 million in net cash proceeds.
Investor Verification Checklist
- Capital Adequacy: Verify the company's ability to secure the "significant additional financing" required to reach clinical trials given the current $432k working capital deficit.
- Stock Subscription Receivable: Confirm the collectability of the $1.2 million stock subscription receivable and the status of the promissory note payments commencing April 2000.
- Regulatory Progress: Assess the status of pre-clinical studies and the timeline for FDA submission, as failure here renders the business model unviable.
- Dilution Risk: Review the impact of recent and subsequent equity issuances (including the 3.6 million shares sold post-period) on existing shareholder value.
- Going Concern Status: Evaluate the likelihood of the company remaining operational without immediate debt restructuring or equity infusion.